纳米药物免疫毒性研究进展  

Progress in immunotoxicity of nanodrugs

作　　者：林曼[1] 洪敏[1] 王庆利[2] 马璟[1] 

机构地区：[1]上海医药工业研究院国家上海新药安全评价与研究中心,上海201203 [2]国家食品药品监督管理局药品审评中心,北京100038

出　　处：《中国药理学与毒理学杂志》2013年第2期299-302,共4页Chinese Journal of Pharmacology and Toxicology

基　　金：国家科技重大专项(2012ZX09505-001-003)~~

摘　　要：纳米药物由于粒径小等特性,极易进入体内,并透过多种生理屏障与免疫细胞或细胞表面蛋白相互作用,发生特异性反应,诱发免疫应答,增强或降低机体的免疫功能。此外,免疫系统自身的复杂性和纳米药物类型多样性增加了研究纳米药物免疫毒性的难度。纳米药物对机体可能具有免疫抑制或免疫刺激包括抗原性、佐剂特性和炎症反应等免疫学特性,不同的纳米药物也已发现可以诱导机体产生不同程度的免疫反应。本文就纳米药物的免疫学特性、免疫系统与纳米药物的相互作用以及不同纳米药物免疫毒性研究方法进行综述。Special properties, such as size, make nanodrugs different from traditional drugs. They can enter organ- isms, blood stream, and then interact with immune cells or proteins in cells, resulting in immunotoxicity of lymphocytes and specific reaction and inducing immune system responses or immune function decline. Furthermore, the complexity of the immune system and the diversity of nanodrugs make difficult evaluattion of their immunotoxicity. Nanodrugs can affect organisms via immune suppression or immune stimulatiion, including antigen and adjuvant properties. Different nanoparticle drugs have been found to have varied impact or the body. The interaction of nanodrugs with the immune system, immuno- logic characters, current research on the immunotoxicity of different nanodrugs and methodology were reviewed.

关 键 词：纳米药物 免疫 毒性 安全性评价 

分 类 号：R99[医药卫生—毒理学]